Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Malley, David M., Neffa, Maryna, Monk, Bradley J., Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M., Bagameri, Andrea, Wang, Edward W., Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887945/
https://www.ncbi.nlm.nih.gov/pubmed/34932394
http://dx.doi.org/10.1200/JCO.21.02067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887945/
https://www.ncbi.nlm.nih.gov/pubmed/34932394
http://dx.doi.org/10.1200/JCO.21.02067

Ejemplares similares